The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Myeloproliferative Neoplasms: A Contemporary Review
Abstract
Polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) constitute the BCR-ABL1-negative myeloproliferative neoplasms and are characterized by mutually exclusive Janus kinase 2 (JAK2), calreticulin (CALR), and myeloproliferative leukemia virus oncogene (MPL) mutations; respective frequencies of these mutations are approximately 95%, 0%, and 0% in PV, 60%, 20%, and 3% in ET, and 60%, 25%, and 7% in PMF. These mutations might be accompanied by other mutations that are less specific to myeloproliferative neoplasms but are prognostically relevant, such as additional sex combs-like 1 (ASXL1). Characteristic bone marrow morphology is required for World Health Organization-compliant diagnosis, especially in distinguishing ET from prefibrotic PMF and masked PV. Survival is the longest in ET, although still inferior to that of the age- and sex-matched control population; median survivals for patients younger than 60 years are approximately 33 years for ET, 24 for PV, and 15 for PMF. Major disease complications include thrombosis and leukemic or fibrotic transformation. In PV and ET, risk factors for survival include older age, leukocytosis, and thrombosis, whereas JAK2 mutation in ET is associated with increased risk of thrombosis. In PMF, type 1 or type 1-like CALR mutations are associated with superior and ASXL1 with inferior survival. Prevention of thrombosis in PV is secured by phlebotomy (hematocrit target <45%) and in both PV and ET by low-dose aspirin therapy; high-risk patients derive additional antithrombotic benefit from cytoreductive therapy with hydroxyurea as first-line and interferon-alfa and busulfan as second-line drugs of choice. Although the JAK inhibitor ruxolitinib was recently approved for use in hydroxyurea-resistant PV, its role in routine clinical practice remains debatable. In myelofibrosis, stem cell transplant is the current treatment of choice for genetically or clinically high-risk disease; for all other patients requiring treatment, participation in clinical trials may be preferred because currently available drugs, including JAK inhibitors, are palliative and not shown to be disease modifying.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933
Age-related clonal hematopoiesis associated with adverse outcomes
Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N., Chavez, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408617 · Cited by 4,841
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
James, C., Ugo, V., Le Couédic, J.-P., Staerk, J., Delhommeau, F., Lacout, C., Garçon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., et al. (2005) · Nature · doi:10.1038/nature03546 · Cited by 3,544
Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence
Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., Chambert, K., Mick, E., Neale, B. M., Fromer, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409405 · Cited by 3,531
Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
Klampfl, T., Gisslinger, H., Harutyunyan, A. S., Nivarthi, H., Rumi, E., Milosevic, J. D., Them, N. C. C., Berg, T., Gisslinger, B., Pietra, D., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1311347 · Cited by 2,003
Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
Nangalia, J., Massie, C. E., Baxter, E. J., Nice, F. L., Gundem, G., Wedge, D. C., Avezov, E., Li, J., Kollmann, K., Kent, D. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1312542 · Cited by 1,756
MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia
Pikman, Y., Lee, B. H., Mercher, T., McDowell, E., Ebert, B. L., Gozo, M., Cuker, A., Wernig, G., Moore, S., Galinsky, I., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030270 · Cited by 1,449
Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
Verstovsek, S., Kantarjian, H., Mesa, R. A., Pardanani, A. D., Cortes-Franco, J., Thomas, D. A., Estrov, Z., Fridman, J. S., Bradley, E. C., Erickson-Viitanen, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002028 · Cited by 1,164
Self-citationGangat, N., Caramazza, D., Vaidya, R., George, G., Begna, K., Schwager, S., Van Dyke, D., Hanson, C., Wu, W., Pardanani, A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2446 · Cited by 1,055
Self-citationEfficacy and Safety of Low-Dose Aspirin in Polycythemia Vera
Landolfi, R., Marchioli, R., Kutti, J., Gisslinger, H., Tognoni, G., Patrono, C., & Barbui, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035572 · Cited by 1,012
Hydroxyurea Compared with Anagrelide in High-Risk Essential Thrombocythemia
Harrison, C. N., Campbell, P. J., Buck, G., Wheatley, K., East, C. L., Bareford, D., Wilkins, B. S., van der Walt, J. D., Reilly, J. T., Grigg, A. P., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043800 · Cited by 927
Cardiovascular Events and Intensity of Treatment in Polycythemia Vera
Marchioli, R., Finazzi, G., Specchia, G., Cacciola, R., Cavazzina, R., Cilloni, D., De Stefano, V., Elli, E., Iurlo, A., Latagliata, R., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208500 · Cited by 846
Hydroxyurea for Patients with Essential Thrombocythemia and a High Risk of Thrombosis
Cortelazzo, S., Finazzi, G., Ruggeri, M., Vestri, O., Galli, M., Rodeghiero, F., & Barbui, T. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504273321704 · Cited by 843
Mutations and prognosis in primary myelofibrosis
Vannucchi, A. M., Lasho, T. L., Guglielmelli, P., Biamonte, F., Pardanani, A., Pereira, A., Finke, C., Score, J., Gangat, N., Mannarelli, C., et al. (2013) · Leukemia · doi:10.1038/leu.2013.119 · Cited by 770
Self-citationTefferi, A., Guglielmelli, P., Larson, D. R., Finke, C., Wassie, E. A., Pieri, L., Gangat, N., Fjerza, R., Belachew, A. A., Lasho, T. L., et al. (2014) · Blood · doi:10.1182/blood-2014-05-579136 · Cited by 737
Self-citationTefferi, A., Rumi, E., Finazzi, G., Gisslinger, H., Vannucchi, A. M., Rodeghiero, F., Randi, M. L., Vaidya, R., Cazzola, M., Rambaldi, A., et al. (2013) · Leukemia · doi:10.1038/leu.2013.163 · Cited by 700
Self-citationBarbui, T., Finazzi, G., Carobbio, A., Thiele, J., Passamonti, F., Rumi, E., Ruggeri, M., Rodeghiero, F., Randi, M. L., Bertozzi, I., et al. (2012) · Blood · doi:10.1182/blood-2012-07-444067 · Cited by 604
Self-citationKiladjian, J.-J., Cassinat, B., Chevret, S., Turlure, P., Cambier, N., Roussel, M., Bellucci, S., Grandchamp, B., Chomienne, C., & Fenaux, P. (2008) · Blood · doi:10.1182/blood-2008-03-143537 · Cited by 583
Effect of Mutation Order on Myeloproliferative Neoplasms
Ortmann, C. A., Kent, D. G., Nangalia, J., Silber, Y., Wedge, D. C., Grinfeld, J., Baxter, E. J., Massie, C. E., Papaemmanuil, E., Menon, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412098 · Cited by 562
Tefferi, A. (2010) · Leukemia · doi:10.1038/leu.2010.69 · Cited by 534
Self-citationBarbui, T., Thiele, J., Passamonti, F., Rumi, E., Boveri, E., Ruggeri, M., Rodeghiero, F., d'Amore, E. S. G., Randi, M. L., Bertozzi, I., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.5298 · Cited by 533
Self-citationCarobbio, A., Thiele, J., Passamonti, F., Rumi, E., Ruggeri, M., Rodeghiero, F., Randi, M. L., Bertozzi, I., Vannucchi, A. M., Antonioli, E., et al. (2011) · Blood · doi:10.1182/blood-2011-02-339002 · Cited by 456
Self-citationRampal, R., Al-Shahrour, F., Abdel-Wahab, O., Patel, J. P., Brunel, J.-P., Mermel, C. H., Bass, A. J., Pretz, J., Ahn, J., Hricik, T., et al. (2014) · Blood · doi:10.1182/blood-2014-02-554634 · Cited by 428
Quintás-Cardama, A., Kantarjian, H., Manshouri, T., Luthra, R., Estrov, Z., Pierce, S., Richie, M. A., Borthakur, G., Konopleva, M., Cortes, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.6075 · Cited by 428
Cervantes, F., Vannucchi, A. M., Kiladjian, J.-J., Al-Ali, H. K., Sirulnik, A., Stalbovskaya, V., McQuitty, M., Hunter, D. S., Levy, R. S., Passamonti, F., et al. (2013) · Blood · doi:10.1182/blood-2013-02-485888 · Cited by 426
Sterkers, Y., Preudhomme, C., Laı̈, J.-L., Demory, J.-L., Caulier, M.-T., Wattel, E., Bordessoule, D., Bauters, F., & Fenaux, P. (1998) · Blood · doi:10.1182/blood.v91.2.616 · Cited by 372
Passamonti, F., Rumi, E., Pietra, D., Elena, C., Boveri, E., Arcaini, L., Roncoroni, E., Astori, C., Merli, M., Boggi, S., et al. (2010) · Leukemia · doi:10.1038/leu.2010.148 · Cited by 370
Oh, S. T., Simonds, E. F., Jones, C., Hale, M. B., Goltsev, Y., Gibbs, K. D., Merker, J. D., Zehnder, J. L., Nolan, G. P., & Gotlib, J. (2010) · Blood · doi:10.1182/blood-2010-02-270108 · Cited by 330
Tefferi, A., Lasho, T. L., Abdel-Wahab, O., Guglielmelli, P., Patel, J., Caramazza, D., Pieri, L., Finke, C. M., Kilpivaara, O., Wadleigh, M., et al. (2010) · Leukemia · doi:10.1038/leu.2010.113 · Cited by 318
Self-citationGenomic and functional analysis of leukemic transformation of myeloproliferative neoplasms
Rampal, R., Ahn, J., Abdel-Wahab, O., Nahas, M., Wang, K., Lipson, D., Otto, G. A., Yelensky, R., Hricik, T., McKenney, A. S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1407792111 · Cited by 301
Pardanani, A., Lasho, T. L., Finke, C., Hanson, C. A., & Tefferi, A. (2007) · Leukemia · doi:10.1038/sj.leu.2404810 · Cited by 298
Self-citationPassamonti, F., Thiele, J., Girodon, F., Rumi, E., Carobbio, A., Gisslinger, H., Kvasnicka, H. M., Ruggeri, M., Randi, M. L., Gangat, N., et al. (2012) · Blood · doi:10.1182/blood-2012-01-403279 · Cited by 277
Self-citationLandgren, O., Goldin, L. R., Kristinsson, S. Y., Helgadottir, E. A., Samuelsson, J., & Björkholm, M. (2008) · Blood · doi:10.1182/blood-2008-03-143602 · Cited by 261
Kiladjian, J.-J., Chevret, S., Dosquet, C., Chomienne, C., & Rain, J.-D. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.0792 · Cited by 255
Alvarez-Larrán, A., Cervantes, F., Pereira, A., Arellano-Rodrigo, E., Pérez-Andreu, V., Hernández-Boluda, J.-C., Ayats, R., Salvador, C., Muntañola, A., Bellosillo, B., et al. (2010) · Blood · doi:10.1182/blood-2010-01-263319 · Cited by 244
Fruchtman, S. M., Mack, K., Kaplan, M. E., Peterson, P., Berk, P. D., & Wasserman, L. R. (1997) · PubMed · Cited by 239
Pascale, S., Petrucci, G., Dragani, A., Habib, A., Zaccardi, F., Pagliaccia, F., Pocaterra, D., Ragazzoni, E., Rolandi, G., Rocca, B., et al. (2012) · Blood · doi:10.1182/blood-2011-06-359224 · Cited by 222
Tefferi, A., Thiele, J., Vannucchi, A. M., & Barbui, T. (2014) · Leukemia · doi:10.1038/leu.2014.35 · Cited by 217
Self-citationGangat, N., Wolanskyj, A. P., McClure, R. F., Li, C.-Y., Schwager, S., Wu, W., & Tefferi, A. (2007) · Leukemia · doi:10.1038/sj.leu.2404500 · Cited by 208
Self-citationJAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths
Tefferi, A. (2012) · Blood · doi:10.1182/blood-2011-11-395228 · Cited by 172
Self-citationInterferon-α therapy in bcr-abl-negative myeloproliferative neoplasms
Kiladjian, J.-J., Chomienne, C., & Fenaux, P. (2008) · Leukemia · doi:10.1038/leu.2008.280 · Cited by 169
Lasho, T. L., Jimma, T., Finke, C. M., Patnaik, M., Hanson, C. A., Ketterling, R. P., Pardanani, A., & Tefferi, A. (2012) · Blood · doi:10.1182/blood-2012-05-429696 · Cited by 167
Self-citationRuxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?
Heine, A., Brossart, P., & Wolf, D. G. F. (2013) · Blood · doi:10.1182/blood-2013-10-531103 · Cited by 163
Barbui, T., Carobbio, A., Rumi, E., Finazzi, G., Gisslinger, H., Rodeghiero, F., Randi, M. L., Rambaldi, A., Gisslinger, B., Pieri, L., et al. (2014) · Blood · doi:10.1182/blood-2014-07-591610 · Cited by 161
Self-citationThe complete evaluation of erythrocytosis: congenital and acquired
Patnaik, M. M., & Tefferi, A. (2009) · Leukemia · doi:10.1038/leu.2009.54 · Cited by 135
Self-citationBuhr, T., Hebeda, K. M., Kaloutsi, V. D., Porwit‐MacDonald, A., van der Walt, J. D., & Kreipe, H. (2011) · Haematologica · doi:10.3324/haematol.2011.047811 · Cited by 113
Primary myelofibrosis: 2014 update on diagnosis, risk‐stratification, and management
Tefferi, A. (2014) · American Journal of Hematology · doi:10.1002/ajh.23703 · Cited by 112
Self-citationMouse models of myeloproliferative neoplasms: JAK of all grades
Li, J., Kent, D. G., Chen, E., & Green, A. R. (2011) · Disease Models & Mechanisms · doi:10.1242/dmm.006817 · Cited by 99
Presence of calreticulin mutations in JAK2-negative polycythemia vera
Broséus, J., Park, J.-H., Carillo, S., Hermouet, S., & Girodon, F. (2014) · Blood · doi:10.1182/blood-2014-06-583161 · Cited by 98
Broséus, J., Alpermann, T., Wulfert, M., Florensa, L., Jeromin, S., Lippert, É., Rozman, M., Lifermann, F., Großmann, V., Haferlach, T., et al. (2013) · Leukemia · doi:10.1038/leu.2013.120 · Cited by 96
Polycythemia Vera and the Myeloproliferative Disorders
Wasserman, L. R., Berk, P. D., & Berlin, N. I. (1995) · Medical Entomology and Zoology · Cited by 83
Finazzi, G., Carobbio, A., Guglielmelli, P., Cavalloni, C., Salmoiraghi, S., Vannucchi, A. M., Cazzola, M., Passamonti, F., Rambaldi, A., & Barbui, T. (2014) · Blood · doi:10.1182/blood-2014-08-596676 · Cited by 82
Álvarez‐Larrán, A., Martinez-Aviles, L. M., Hernández‐Boluda, J. C., Ferrer‐Marín, F., Antelo, M. L., Burgaleta, C., Mata, M. I., Xicoy, B., Martínez‐Trillos, A., Gómez‐Casares, M. T., et al. (2014) · Annals of Hematology · doi:10.1007/s00277-014-2152-7 · Cited by 81
Bonicelli, G., Abdulkarim, K., Mounier, M., et al. (2012) · British Journal of Haematology · doi:10.1111/bjh.12117 · Cited by 81
Polycythemia vera‐associated pruritus and its management
Saini, K. S., Patnaik, M. M., & Tefferi, A. (2010) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2010.02334.x · Cited by 79
Self-citationInterferon Alfa Therapy in CALR-Mutated Essential Thrombocythemia
Cassinat, B., Verger, E., & Kiladjian, J. (2014) · New England Journal of Medicine · doi:10.1056/nejmc1401255 · Cited by 76
Tefferi, A., Finke, C. M., Lasho, T. L., Wassie, E. A., Knudson, R. A., Ketterling, R. P., Hanson, C. A., & Pardanani, A. D. (2013) · Leukemia · doi:10.1038/leu.2013.286 · Cited by 76
Self-citationBusulphan is safe and efficient treatment in elderly patients with essential thrombocythemia
Shvidel, L., Sigler, E., Haran, M. Z., Klepfish, A., Duek, A., Berrébi, A., & Shtalrid, M. (2007) · Leukemia · doi:10.1038/sj.leu.2404743 · Cited by 55
JAK2V617F allele burden is reduced by busulfan therapy: a new observation using an old drug
Kuriakose, E. T., Gjoni, S., Wang, Y. L., Baumann, R., Jones, A. V., Cross, N. C. P., & Silver, R. T. (2013) · Haematologica · doi:10.3324/haematol.2013.087742 · Cited by 37
Profile of pacritinib and its potential in the treatment of hematologic disorders
Hatzimichael, E. C., Tsolas, E., & Briasoulis, E. C. (2014) · Journal of Blood Medicine · doi:10.2147/jbm.s51253 · Cited by 25
Cited by
Short, N. J., Rytting, M. E., & Cortes, J. E. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31041-9 · Cited by 781
Tefferi, A., & Barbui, T. (2020) · American Journal of Hematology · doi:10.1002/ajh.26008 · Cited by 352
Self-citationA Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis
Tefferi, A., Lasho, T. L., Begna, K. H., Patnaik, M. M., Zblewski, D. L., Finke, C. M., Laborde, R. R., Wassie, E., Schimek, L., Hanson, C. A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1310523 · Cited by 325
Self-citationPrimary myelofibrosis: 2021 update on diagnosis, risk‐stratification and management
Tefferi, A. (2021) · American Journal of Hematology · doi:10.1002/ajh.26050 · Cited by 315
Self-citationTargeted deep sequencing in polycythemia vera and essential thrombocythemia
Tefferi, A., Lasho, T. L., Guglielmelli, P., Finke, C. M., Rotunno, G., Elala, Y., Pacilli, A., Hanson, C. A., Pancrazzi, A., Ketterling, R. P., et al. (2016) · Blood Advances · doi:10.1182/bloodadvances.2016000216 · Cited by 311
Self-citation
Metadata
- Authors
- Tefferi, A., & Pardanani, A.
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2015-04-01
- Volume
- 1
- Issue
- 1
- Pages
- 97
- ISSN
- 2374-2437 (ISSN-L)
- OpenAlex
- W2030356048
- Cited by
- 342
- References
- 60
- FWCI
- 16.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.